Description

Advagraf (tacrolimus) Capsules with Prolonged Release 0.5 mg. №50

Ingredients

Active ingredient: Tacrolimus
Other ingredients: Hypromellose, lactose monohydrate, croscarmellose sodium, magnesium stearate, and others.

Dosage

Dosage: The usual starting dose is 0.1 to 0.15 mg/kg once daily. Dosage may vary based on individual patient factors. Consult a healthcare provider for the appropriate dosage.

Indications

Indicated for: Prevention of organ rejection in patients receiving allogeneic liver, kidney, or heart transplants.

Contraindications

Contraindications: Hypersensitivity to tacrolimus or any component of the formulation. Patients with uncontrolled hypertension or malignancies.

Directions

Administration: Swallow the capsule whole with a glass of water. Do not crush or chew the capsule. Take consistently at the same time each day.

Scientific Evidence

Tacrolimus, the active ingredient in Advagraf, is a calcineurin inhibitor that exerts its immunosuppressive effects by inhibiting T-lymphocyte activation. This mechanism helps prevent organ rejection in transplant patients. Clinical studies have demonstrated the efficacy of tacrolimus in improving graft survival rates and reducing the risk of rejection compared to other immunosuppressants.

Additional Information

It is essential to monitor tacrolimus blood levels regularly to ensure therapeutic efficacy and avoid toxicity. Common side effects may include tremors, hypertension, and renal dysfunction. Patients should be closely monitored for signs of adverse effects and drug interactions.

Research has shown that prolonged-release formulations of tacrolimus, such as Advagraf, offer improved patient adherence and convenience compared to immediate-release formulations. This can lead to better long-term outcomes in transplant recipients by maintaining consistent drug levels in the body.